Evidence map›Paper›PMID 29749992›Full record

ArticleIranian journal of medical sciences2018

A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy.

Hossein Moravej, Anis Amirhakimi, Alireza Showraki, Hamid Amoozgar, Zahra Hadipour, Ghasem Nikfar

Open access · greenAbstract readCase Reports
In one paragraph

Article in Iranian journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hossein MoravejNeonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Anis AmirhakimiDepartment of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza ShowrakiSchool of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hamid AmoozgarNeonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra HadipourDepartment of Medical Genetics, Sarem Cell Research Center and Hospital, Tehran, Iran.
Ghasem NikfarDepartment of Pediatrics, Fasa University of Medical sciences, Fasa, Iran.
Shiraz University of Medical Sciences · IRFasa University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pompe disease (PD), also known as "glycogen storage disease type II (OMIM # 232300)" is a rare autosomal recessive disorder characterized by progressive glycogen accumulation in cellular lysosomes. It ultimately leads to cellular damage. Infantile-onset Pompe disease (IOPD) is the most severe type of this disease and is characterized by severe hypertrophic cardiomyopathy and generalized hypotonia. Mutations in the

Indexed as

CardiomyopathyEnzyme replacement therapyGAA proteinGlycogen storage disease type IIHumanHypertrophy

Identifiers

PMID29749992
PMCPMC5936855
OpenAlexW2656722310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.